

September 13, 2013

## Announcements

### Comprehensive Cancer Center Designation Renewed

Yale Cancer Center's designation as a comprehensive cancer center by the National Cancer Institute (NCI) was recently extended for an additional 5 years following an extensive grant submission and review process. The award includes \$12.2 million in funding over 5 years to support the Center's 7 research programs and 8 shared resources, along with the continuation of the Center's comprehensive status, the most prestigious level of designation from the NCI.

I am extremely grateful for the dedication and support of my colleagues at Yale Cancer Center, Smilow Cancer Hospital at Yale-New Haven, and Yale School of Medicine for their immense contributions to the grant submission. As we begin our next funding period from the NCI, I look forward to continuing to work together to strengthen and build our translational research and clinical trials efforts, while expanding our team of clinicians and outpatient locations.

[Read More >>](#)

### Steven Gore Named Director of Hematologic Malignancies

I am proud to announce that we have appointed Steven D. Gore, MD, an internationally known hematologist, as Director of Hematologic Malignancies at Smilow Cancer Hospital and Yale Cancer Center. Dr. Gore joins us from The Johns Hopkins University School of Medicine and will begin his new appointment on November 1, 2013.



Dr. Gore's focus on clinical trials for patients with leukemia will bring renewed opportunities to Smilow for our patients.

*from the desk of*

**Thomas J. Lynch, Jr., MD**

Director, Yale Cancer Center

Physician-in-Chief Smilow Cancer

Hospital at Yale-New Haven



### Join Yale Cancer Center on Facebook

Like us on Facebook 

### Follow Yale Cancer Center on Twitter

Follow us on 

### Closer to Free

**closer to free**

The fund to advance cancer research and enhance patient care

### Links of Interest

#### CV Library

The CV library is a new resource available to our members, with

As Director of Hematologic Malignancies, his leadership will help to drive our Program forward in partnership with Madhav Dhodapkar, Chief of Hematology.

[Read More >>](#)

**Mario Sznol Named  
Deputy Section  
Chief of Medical Oncology**

I am pleased to announce that Roy Herbst has named Dr. Mario Sznol as our deputy medical oncology section chief. Mario is currently Professor of Medicine and Leader of the Melanoma Program. Formally with the National Cancer Institute with additional experience in biotech, Mario has an international reputation in cancer drug development especially in cancer immunotherapy, and the treatment of patients with melanoma and renal cell carcinoma. Mario is working to expand our opportunities for clinical trials at Yale Cancer Center, and his work has had an impact on all our disease programs since he has brought the immune checkpoint inhibitors to Yale, which have helped our patients and our academic mission.



Mario will work closely with Roy as we continue to expand the section of medical oncology with a focus on excellent, protocol directed clinical care. He will also continue to serve as a mentor to junior faculty. Please join me in congratulating Mario on this well-deserved honor.

**Commission on Cancer Site Review**

The Yale Cancer Center - Smilow Cancer Hospital at Yale-New Haven Cancer Program is approved by the American College of Surgeons--Committee on Cancer (ACoS-CoC) through a review every three years. Yale Cancer Center has submitted our written summary, under the leadership of Dr. David Fischer, of our compliance with their standards and documentation of that compliance. In addition, copies of our Annual Cancer Program Reports for 2010, 2011 and 2012 have been submitted.

We will welcome an assigned reviewer from the ACoS-CoC on Thursday, October 31 for a tour of Smilow Cancer Hospital and meetings with members of the Cancer Committee, the Yale Tumor Registry, and the Cancer Liaison Physician.

CVs of post-docs and others looking for positions at Yale. Please browse the listings if you have openings, and send the CVs you receive to share.

[Learn More >>](#)

**In the News**

Read recent articles featuring experts from Yale Cancer Center.

[Read More >>](#)

**Subscribe to Yale Cancer Center Answers on iTunes**

Yale Cancer Center's weekly radio program on CT Public Radio is ranked number 2 in the world for cancer programs on iTunes. Subscribe to the show.

[Learn More >>](#)

**Yale Cancer Center Grand Rounds**

Video presentations from Yale Cancer Center members are now available online.

[Learn More >>](#)

**DirectConnect Archives**

[Learn More >>](#)

**ASCO Connection Blog**

The Power of Cancer  
by Anees Chagpar, MD

[Read More >>](#)

---

**Events**

**September 13; 1:00 PM  
Yale Cancer Center  
Molecular Virology Research  
Program**

SHM I-116

*Discovery of Functional RNAs  
and RNA Structures in  
Epstein-Barr Virus*

Walter Moss, PhD

[Learn More >> \(PDF\)](#)

**September 15; 6:00 PM  
Yale Cancer Center Answers**

WNPR

*Ovarian Cancer Awareness*

Heather Glazer and Rachel Hayes

[Learn More >>](#)

### Prostate Cancer CME Symposium

Please join us for our evening oncology series on Wednesday, September 25, 2013 highlighting Prostate & Urologic Cancers at Smilow Cancer Hospital. This interactive, case-based series will provide the audience with relevant information on diagnosis, currently accepted guidelines for management, and the use of novel and multi-modality therapies for prostate and urologic cancers, including precision guided IMRT and 4 D Radiotherapy, active surveillance for prostate cancer, novel agents for refractory prostate cancer, new drugs for the treatment of bladder cancer, surgical management of bladder cancer, and hereditary kidney cancer.

[Learn More >>](#)

## Notables

**Hyundai Hope On Wheels** and New Haven-area Hyundai dealers have awarded a \$250,000 Hyundai Hope Grant for pediatric cancer research to **Dr. Kavita Dhodapkar**. The grant funds will support her research focused on developing personalized vaccines for the treatment of pediatric brain tumors.

**Christina Dreyfus** has joined the Research Administration team, under the leadership of Chad Ellis, PhD, as a program coordinator. A graduate of Brandeis University, Christina has extensive background in writing and editing, and clinical research experience at Yale's Department of Psychiatry and the Harvard School of Public Health. She will assist Yale Cancer Center's Research Programs with program summaries, monthly meetings, and grant applications, and also assist with our membership guidelines and staff the membership committee. Please welcome Christina to the Cancer Center.



## Closer to Free

Last week's Closer to Free Ride was amazing! We had over 900 riders participate and 400 volunteers, and the fundraising totals are approaching \$1 million! Thank

you to the physicians, nurses, and staff who came out and rode, volunteered, or cheered to support our signature Closer to Free fundraising event. There's still time to support a rider's fundraising goals through the Ride [website](#).

### September 16; 12:30 PM Yale Cancer Center Cancer Prevention and Control Research Program

60 College Street  
*Recent Developments in Breast  
Reconstruction*  
Stephanie Kwei, MD  
[Learn More >>](#)

### September 16; 3:00 PM Yale Cancer Center Signal Transduction Program

SHM I-116  
*The Androgen Receptor as a  
Target for Castration Resistant  
Prostate Cancer*  
Daniel Petrylak, MD

[Learn More >>](#) (PDF)

### September 17; 9:30 AM Pathology Research in Progress Talks

The Anlyan Center, N-107  
*Malignant Melanoma: Signaling  
Pathways that Drive Tumor  
Formation and Progression*  
Marcus Bosenberg MD, PhD  
[Learn More >>](#)

### September 17; 12:00 PM Smilow Cancer Hospital Town Hall Meeting

Park Street Auditorium  
[Learn More >>](#) (PDF)

### September 19; 5:30 PM Yale Cancer Center / Smilow Cancer Hospital Seminar

Park Street Auditorium  
*The Advantages of Breast  
Tomosynthesis*  
[Learn More >>](#) (PDF)

### September 21 CT Women of Hope's Ovarian Cancer Event

Hammonasset Beach State  
Park  
*First Annual Ann Miller 5K  
Costume Walk*  
[Learn More >>](#) (PDF)

### September 22; 6:00 PM Yale Cancer Center Answers WNPR

Roy Herbst shared the following story from his day out on the ride course. There were many more inspiring stories like this that helped to make everyone's day special. If you didn't have a chance to participate, please take a moment to view the online galleries of photos and news coverage of the event so you can see just how memorable it was.

"Yesterday, I rode the Closer to Free ride and was happy to see so many of you participating along with our colleagues from throughout YCC and many of our patients/supporters. Around mile 40, just after the Guilford Green (as I was about to call a taxi home), I was passed briskly by a cyclist who then turned around to introduce himself - it turns out he is a melanoma patient of Harriet who is currently on the nivolumab/ipilimumab trial and doing great. He could not say nicer things about Harriet, Matt, the melanoma program, Smilow, our doctors, and our entire staff. I must tell you, I have never had a more inspiring interaction with a patient! (and of course how could I then myself not finish the ride). It again made me realize that we are really making a difference together as we deliver the most comprehensive, compassionate and when possible protocol driven care." - Roy Herbst, MD, PhD, Chief of Medical Oncology

*Support Services for  
Cancer Patients*  
Bonnie Indeck, LCSW  
[Learn More >>](#)

**September 24: 9:30 AM  
Pathology Research in  
Progress Talks**

The Anlyan Center, N-107  
*Arpeggio: Harmonic  
Compression of ChIP-seq  
Data Reveals Protein-Chromatin  
Interaction Signatures*  
Kelly Stanton  
TBD  
Siyuan Ding  
[Learn More >>](#)

**September 24; 12:00 PM  
Yale Cancer Center Grand  
Rounds**

Park Street Auditorium  
*Presurgical Trials in Breast  
Cancer: Role in Clinical  
Development and Discovery  
Mechanisms of Drug Resistance*  
Carlos Arteaga, MD  
[Learn More >> \(PDF\)](#)

**September 25; 4:30 PM  
Yale Cancer Center Evening  
Oncology Series**

NP 4-101 A and B  
*Prostate and Urologic Cancers*  
[Learn More >> \(PDF\)](#)

**September 27; 1:00 PM  
Yale Cancer Center Special  
Seminar**

NP 4-101 A  
*The Secret of the Thundergod  
Vine*  
Daniel Von Hoff, MD  
[Learn More >> \(PDF\)](#)

---

## **Employment Opportunities**

We seek your assistance in the recruitment of qualified Oncology Research Nurses to join the Cancer Center for full time research opportunities. Positions traditionally require a minimum of BSN and 4 years of research nursing experience with a strong preference within





[Facebook Page with Photos >>](#)  
[News Clips >>](#)

## Funding and Award Opportunities

Women's Health Research at Yale Pioneer and Pilot

oncology. In lieu of research experience, trained oncology nurses with little or no research experience are considered for positions of the same level. Should you know of any potential candidates, please encourage them to go on-line to [www.yale.edu/jobs](http://www.yale.edu/jobs) and navigate to the STARS employment website in search of positions 18343BR and 18943BR, upload the resume and apply. They may also contact [Sandra Greer](#) for further information.

### Submissions

Please submit your recent publication and grant announcements to:

**Renee Gaudette**  
Director, Public Affairs and Marketing

[renee.gaudette@yale.edu](mailto:renee.gaudette@yale.edu)

 Forward to a Friend

### **Project Opportunities**

The Pioneer and Pilot Project Program Awards are provided to investigators who are full-time Yale faculty. Because we are interested in encouraging interdisciplinary and inter-institutional research, investigators outside the Yale community are invited to collaborate with Yale principal investigators.

**Letters of Intent Due:** October 21, 2013

[Learn More >>](#)

### **The Mathew Larson Foundation for Pediatric Brain Tumor Research**

The Mathew Larson Foundation for Pediatric Brain Tumor Research seeks to fund translational and clinical projects in Pediatric Brain Tumor Research. The Primary Investigator on the application must be an MD or PhD at a not-for-profit, medical or scientific institution and must hold an academic rank of assistant professor (or equivalent) or instructor (or equivalent.) Investigators at higher ranks are excluded. Investigators at multiple institutions are invited to submit joint applications as long as both institutions give permission and agree to abide by all Foundation requirements.

**Pre-Application Deadline:** October 27, 2013

[Learn More >>](#)

### **Hope Funds for Cancer Research**

The Hope Funds for Cancer Research is pleased to announce a request for research proposals for postdoctoral fellows working in oncology. These 3-year fellowships will be awarded to postdoctoral scientists commencing in 2014 with stipends of \$48,000 for the first year, \$50,000 for the second year, and \$52,000 for the third year.

**Application Deadline:** September 19, 2013

[Learn More >>](#)

### **ASH Bridge Grant Program**

In 2013 and for the next two years, ASH's new bridge grant program will provide at least 30 one-year awards annually, in the amount of \$100,000 each, to ASH members who applied for an NIH R01 grant or equivalent but were denied funding due to budget cutbacks. The long-term goal of the award is to help sustain recipients' research and contribute to their retention in hematology investigation.

**Application Deadline:** November 1, 2013

[Learn More >>](#)

### **CT Department of Public Health Funding**

The Connecticut Department of Public Health is seeking proposals for innovative Connecticut-based biomedical research projects in the fields of heart disease, cancer and other tobacco-related diseases, Alzheimer's disease, stroke,

and diabetes.

Funds may be used to conduct new research or to enhance existing projects.

- Each contract award resulting from this RFP will range from approximately \$300,000 to \$1,000,000(including 15% indirect costs)
- Total funding available: \$2,696,665 for up to 8 awards.
- The proposal budget and work plan should be developed for a one-year period.
- Resulting contracts will be awarded for a two-year period to allow time for startup issues and unexpected delays in the conduct of funded research.
- Multiple proposals from the same institution will be accepted as long as the research proposals have different goals.

**Proposal Deadline:** October 21, 2013

[Learn More >>](#)

#### **CDMRP Breast Cancer Research Program**

The CDMRP Breast Cancer Research Program has just announced a second round of funding available for its Breakthrough Awards.

Key Mechanism Elements

- Supports promising research that has the potential to lead to or make breakthroughs in breast cancer.
- Potential impact of the research may be near-term or long-term, but it must be significant and move beyond an incremental advancement.

**Pre-Application Submission Deadline:** October 8, 2013

[Learn More >>](#)

---

## **Employee Profile: Liz Cornelio**

*The Employee Profile recognizes the diverse contributions made by Yale Cancer Center and Smilow Cancer Hospital staff to meet our patient care, research, education, and outreach goals. The staff profiled are examples of the great work being done here, and the dedication and values we possess.*

*To suggest someone to be profiled, please contact*

*[Emily Fenton](#).*

Five years ago Liz Cornelio started as a Financial Assistant with Yale Cancer Center. Since then she has been promoted to Assistant Administrator for Hematology, Palliative Care, the Smilow Cancer Hospital Care Centers, and Neuro-Oncology, and is also responsible for managing the section's Financial Assistant and Accountant positions. Her day to day tasks include managing department accounts, verifying accuracy of charges, and serving as a contact person for faculty, administrative staff and lab personnel on a variety of issues as well as departmental budgeting.



A lot of what Liz does is focused on managing and analyzing grants as well as other departmental accounts including the management of faculty funding including endowments, gifts, dowry's and shared services. Within this role she must keep track of all the finances and ensure that the funds are being utilized correctly and within the guidelines of the award and the University.

"It is rewarding to be able to help a faculty member utilize the funds they have available to achieve the goals of their research, which are ultimately the goals of the entire Cancer Center," Liz said.

Jennifer Mulligan, Associate Director for Finance and Administration for the Cancer Center, commented, "Liz has been with the Cancer Center since 2008 and has internally been promoted within the finance ranks twice, which speaks loudly to Liz's accomplishments. We are very lucky to have her as a leader within the Cancer Center Business Office."

---

## Recent Publications

### **The Healthy Eating Index 2005 and Risk for Pancreatic Cancer in the NIH-AARP Study.**

Arem H, Reedy J, Sampson J, Jiao L, Hollenbeck AR, Risch H, Mayne ST, Stolzenberg-Solomon RZ.

J Natl Cancer Inst. 2013 Sep 4;105(17):1298-305.

[Read More >>](#)

### **Antigen-specific, antibody-coated, exosome-like nanovesicles deliver suppressor T-cell microRNA-150 to effector T cells to inhibit contact sensitivity.**

Bryniarski K, Ptak W, Jayakumar A, Püllmann K, Caplan MJ, Chairoungdua A, Lu J, Adams BD, Sikora E, Nazimek K,



Marquez S, Kleinstein SH, Sangwung P, Iwakiri Y, Delgado E, Redegeld F, Blokhuis BR, Wojcikowski J, Daniel AW, Groot Kormelink T, Askenase PW.

J Allergy Clin Immunol. 2013 Jul;132(1):170-81.

[Read More >>](#)

**Proceedings from the National Cancer Institute's Second International Workshop on the Biology, Prevention, and Treatment of Relapse After Hematopoietic Stem Cell Transplantation: Part I. Biology of Relapse after Transplantation.**

Gress RE, Miller JS, Battiwalla M, Bishop MR, Giralt SA, Hardy NM, Kröger N, Wayne AS, Landau DA, Wu CJ.

Biol Blood Marrow Transplant. 2013 Sep 6.

[Read More >>](#)

**HER2/neu gene amplification determines the sensitivity of uterine serous carcinoma cell lines to AZD8055, a novel dual mTORC1/2 inhibitor.**

English DP, Roque DM, Carrara L, Lopez S, Bellone S, Cocco E, Bortolomai I, Schwartz PE, Rutherford T, Santin AD.

Gynecol Oncol. 2013 Sep 4.

[Read More >>](#)

**Adverse Health Outcomes Associated with Surgical Management of the Small Renal Mass.**

Shuch B, Hanley JM, Lai JC, Vourganti S, Setodji CM, Dick AW, Chow WH, Saigal CS; The Urologic Diseases in America Project.

J Urol. 2013 Sep 5.

[Read More >>](#)

**Class III  $\beta$ -tubulin overexpression within the tumor microenvironment is a prognostic biomarker for poor overall survival in ovarian cancer patients treated with neoadjuvant carboplatin/paclitaxel.**

Roque DM, Buza N, Glasgow M, Bellone S, Bortolomai I, Gasparrini S, Cocco E, Ratner E, Silasi DA, Azodi M, Rutherford TJ, Schwartz PE, Santin AD.

Clin Exp Metastasis. 2013 Sep 5.

[Read More >>](#)

**3.0 Tesla vs 1.5 Tesla breast magnetic resonance imaging in newly diagnosed breast cancer patients.**

Butler RS, Chen C, Vashi R, Hooley RJ, Philpotts LE.

World J Radiol. 2013 Aug 28;5(8):285-94.

[Read More >>](#)

**Low-copy piggyBac transposon mutagenesis in mice identifies genes driving melanoma.**

Ni TK, Landrette SF, Bjornson RD, Bosenberg MW, Xu T.

Proc Natl Acad Sci U S A. 2013 Sep 3.

[Read More >>](#)

**Denosumab for Patients With Persistent or Relapsed Hypercalcemia of Malignancy Despite Recent Bisphosphonate Treatment.**

Hu MI, Glezerman I, Leboulleux S, Insogna K, Gucalp R, Misiorowski W, Yu B, Ying W, Jain RK.

J Natl Cancer Inst. 2013 Aug 29.

[Read More >>](#)

**Dissecting Social Cell Biology and Tumors Using Drosophila Genetics.**

Pastor-Pareja JC, Xu T.

Annu Rev Genet. 2013 Aug 22.

[Read More >>](#)

**Warthin's Tumor Multimodality Imaging. Anatomical and Scintigraphy Imaging Review, Including PET-CT and SPECT-CT.**

Djekidel M, Wang P, Piert M, Mukherji SK, Brown RK

OMICS J Radiology 2: 117 doi:10.4172/2167-

7964.1000117

**Pre-Treatment FDG PET Bone Marrow (BM) Uptake and Disease Involvement. Can Semiquantitative Measures Discriminate Between A Normal, Hypercellular or Infiltrated Bone Marrow?**

Ahmed R, Yao X, Fourzali Y, Djekidel M

J Bone Marrow Res 1: 115. doi:10.4172/jbmr.1000115

**The Metabolic Signature of Tumors as an Imaging Biomarker in Staging, Restaging and Therapy Response on FDG PET. OMICS J**

Djekidel M (2013)

Radiology 2: 116 doi:10.4172/2167-7964.1000116